phrykt

Cytosorbents Corp (CTSO): who owns it and who trades it

As of Oct 30, 2026, CTSO insiders reported 10 purchases worth $269K in the last 12 months. The largest buyer was Phillip P. Chan (CEO), with $198K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, CTSO insiders reported $269K of open-market purchases and $0 of sales.

Purchases, 12 months
$269K
10 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 15, 2026
Filed Sep 16, 2026

Purchases and sales by month

$149K$149KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 15, 2026Phillip P. ChanCEOPurchase3,774$6.00$22.6KForm 4
Sep 15, 2026Alan D. SobelDirectorPurchase100$6.01$601Form 4
Sep 15, 2026Alan D. SobelDirectorPurchase1,900$6.12$11.6KForm 4
Sep 15, 2026Alan D. SobelDirectorPurchase500$6.05$3KForm 4
Sep 14, 2026Vincent CapponiPresidentPurchase273$5.90$1.6KForm 4
Sep 14, 2026Vincent CapponiPresidentPurchase1,800$6.07$10.9KForm 4
Sep 4, 2026Phillip P. ChanCEOPurchase200,000$0.35$70KForm 4
Jun 15, 2026Peter J MarianiCFOPurchase100,000$0.44$44KForm 4
Jun 15, 2026Phillip P. ChanCEOPurchase10,333$0.43$4.4KForm 4
Jun 12, 2026Phillip P. ChanCEOPurchase251,136$0.40$100KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Phillip P. ChanChief Executive Officer, Director$198K–Sep 15, 2026
Peter J MarianiChief Financial Officer$44K–Jun 15, 2026
Alan D. SobelDirector$15.3K–Sep 15, 2026
Vincent CapponiPresident and COO$12.5K–Sep 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CTSO short interest

Low short interest. 0.2% of CTSO shares are sold short: about 1 share in 466. Over the last 12 reports the number of shares short went down 93%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 134,896 CTSO shares were sold short, 0.2% of the shares outstanding, up 17.9% from the report before. At the average daily volume of 121,466 shares, buying them all back would take about 1.1 trading days (days to cover).

Shares short, % of all shares

0.21%May 15Oct 304.19%

Days to cover

1.1May 15Oct 3043.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026134,8960.21%+18%121,4661.1
Oct 15, 2026114,4020.18%-8%11,13610.3
Sep 30, 2026123,8900.20%+3%10,33912.0
Sep 15, 2026120,6060.19%-95%45,5522.6
Aug 31, 20262.31M3.67%+7%126,00818.3
Aug 14, 20262.16M3.43%+1%72,24929.9
Jul 31, 20262.14M3.41%+1%55,88838.3
Jul 15, 20262.12M3.38%+2%78,87226.9
Jun 30, 20262.08M3.32%-0%333,4386.2
Jun 15, 20262.09M3.33%+1%264,2737.9
May 29, 20262.07M3.30%+1%111,88718.5
May 15, 20262.06M3.28%+1%99,84820.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cytosorbents company events

Cytosorbents filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (listing). The latest was on Sep 23, 2026.

  1. Sep 23, 2026AnnouncementAs previously disclosed, on October 2, 2025, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for… Filing
  2. Sep 8, 2026RulesChanged its bylaws or articles. Filing
  3. Aug 14, 2026VoteReported shareholder vote results. Filing
  4. Aug 7, 2026AnnouncementShared information with investors. Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jul 6, 2026ListingCytoSorbents Corporation, a Delaware corporation, received a written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the Company’s minimum Market Value of Listed Securities was below… Filing
  7. Jun 25, 2026AnnouncementShared information with investors. Filing
  8. May 13, 2026ResultsReleased financial results. Filing
  9. Apr 2, 2026ListingCytoSorbents Corporation, a Delaware corporation, received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC advising that the Company has been granted a 180-day extension, or until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid… Filing
  10. Mar 25, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cytosorbents financials

Questions about Cytosorbents Corp (CTSO) stock

Are CTSO insiders buying or selling?

In the last 12 months, CTSO insiders reported 10 open-market purchases worth $269K and no sales. The latest trade was on Sep 15, 2026. See every trade.

What is the short interest in CTSO?

As of Oct 30, 2026, 134,896 CTSO shares were sold short, 0.2% of the shares outstanding, up 17.9% from the report before. At the average daily volume of 121,466 shares, buying them all back would take about 1.1 trading days (days to cover). See the history.

Executive pay

Cytosorbents's chief executive was paid a total of $808K for the year ended Dec 31, 2025, down 10% from $900K the year before. In the last 12 months, Cytosorbents's executives and directors bought $269K of stock on the open market and sold none.

Chief executive, total pay$808KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$723KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$679KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.